These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 14647037)

  • 1. Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy.
    Yang T; Brittenham GM; Dong WQ; Levy MN; Obejero-Paz CA; Kuryshev YA; Brown AM
    J Lab Clin Med; 2003 Nov; 142(5):332-40. PubMed ID: 14647037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy.
    Obejero-Paz CA; Yang T; Dong WQ; Levy MN; Brittenham GM; Kuryshev YA; Brown AM
    J Lab Clin Med; 2003 Feb; 141(2):121-30. PubMed ID: 12577048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetaminophen protects against iron-induced cardiac damage in gerbils.
    Walker EM; Epling CP; Parris C; Cansino S; Ghosh P; Desai DH; Morrison RG; Wright GL; Wehner P; Mangiarua EI; Walker SM; Blough ER
    Ann Clin Lab Sci; 2007; 37(1):22-33. PubMed ID: 17311866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optical mapping reveals conduction slowing and impulse block in iron-overload cardiomyopathy.
    Laurita KR; Chuck ET; Yang T; Dong WQ; Kuryshev YA; Brittenham GM; Rosenbaum DS; Brown AM
    J Lab Clin Med; 2003 Aug; 142(2):83-9. PubMed ID: 12960954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of deferasirox in preventing cardiovascular complications in the iron-overloaded gerbil.
    Al-Rousan RM; Manzoor K; Paturi S; Arvapalli RK; Laurino JP; Darnon L; Walker EM; Blough ER
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):117-25. PubMed ID: 21593444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimodal cardiac dysfunction in an animal model of iron overload.
    Yang T; Dong WQ; Kuryshev YA; Obejero-Paz C; Levy MN; Brittenham GM; Kiatchoosakun S; Kirkpatrick D; Hoit BD; Brown AM
    J Lab Clin Med; 2002 Oct; 140(4):263-71. PubMed ID: 12389025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function.
    Gao S; Long CL; Wang RH; Wang H
    Cardiovasc Res; 2009 Aug; 83(3):444-56. PubMed ID: 19304734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetaminophen combinations protect against iron-induced cardiac damage in gerbils.
    Walker EM; Morrison RG; Dornon L; Laurino JP; Walker SM; Studeny M; Wehner PS; Rice KM; Wu M; Blough ER
    Ann Clin Lab Sci; 2009; 39(4):378-85. PubMed ID: 19880766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals.
    Dendorfer A; Heidbreder M; Hellwig-Bürgel T; Jöhren O; Qadri F; Dominiak P
    Free Radic Biol Med; 2005 Jan; 38(1):117-24. PubMed ID: 15589380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.
    Anderson LJ; Westwood MA; Holden S; Davis B; Prescott E; Wonke B; Porter JB; Walker JM; Pennell DJ
    Br J Haematol; 2004 Nov; 127(3):348-55. PubMed ID: 15491298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Deferoxamine protects against gentamicin ototoxicity].
    Chen Y; Wang J; Huang W
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1999 Jun; 34(3):154-6. PubMed ID: 12764806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity.
    Sterba M; Popelová O; Simunek T; Mazurová Y; Potácová A; Adamcová M; Kaiserová H; Ponka P; Gersl V
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1336-47. PubMed ID: 17003229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
    Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A
    J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted overexpression of growth hormone by adenoviral gene transfer preserves myocardial function and ventricular geometry in ischemic cardiomyopathy.
    Jayasankar V; Pirolli TJ; Bish LT; Berry MF; Burdick J; Grand T; Woo YJ
    J Mol Cell Cardiol; 2004 Apr; 36(4):531-8. PubMed ID: 15081312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
    Otto-Duessel M; Brewer C; Gonzalez I; Nick H; Wood JC
    Acta Haematol; 2008; 120(2):123-8. PubMed ID: 19018129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload.
    Jiang H; Luan Z; Wang J; Xie J
    Neurochem Int; 2006 Nov; 49(6):605-9. PubMed ID: 16806586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine.
    Wongjaikam S; Kumfu S; Khamseekaew J; Chattipakorn SC; Chattipakorn N
    Sci Rep; 2017 Mar; 7():44460. PubMed ID: 28287621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of drug therapy on myocardial hypertrophy in left ventricular failure.
    Taylor SH
    J Cardiovasc Pharmacol; 1987; 10 Suppl 6():S141-7. PubMed ID: 2485020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy.
    Woo YJ; Grand TJ; Berry MF; Atluri P; Moise MA; Hsu VM; Cohen J; Fisher O; Burdick J; Taylor M; Zentko S; Liao G; Smith M; Kolakowski S; Jayasankar V; Gardner TJ; Sweeney HL
    J Thorac Cardiovasc Surg; 2005 Aug; 130(2):321-9. PubMed ID: 16077394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.